Startups
2016
MODIS THERAPEUTICSDeveloping treatments for rare genetics diseases
Company adquired by Zogenix https://zogenix.com/ for 250M€ (2019)
Company adquired by Zogenix https://zogenix.com/ for 250M€ (2019)
Address
13th Street 409, 94612 Oakland, United States of America
CERCA ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. We were formed in 2016 through a collaboration with academic experts in mitochondrial biology. Our lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease.
ABOUT TK2 DEFICIENCY - A progressive, devastating mitochondrial disease
Thymidine kinase 2 deficiency is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal.
ABOUT TK2 DEFICIENCY - A progressive, devastating mitochondrial disease
Thymidine kinase 2 deficiency is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal.
Product description
Modis' lead product is MT1621, a deoxynucleoside combination therapy, in advanced development, for the treatment of thymidine kinase 2 deficiency (TK2d).
Company Closed or Exit Year